These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 15693648)

  • 1. PET imaging in the assessment of normal and impaired cognitive function.
    Silverman DH; Alavi A
    Radiol Clin North Am; 2005 Jan; 43(1):67-77, x. PubMed ID: 15693648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Molecular neuroimaging in the study of cognitive impairment: contribution of the cerebral blood flow SPECT with 99mTc-HMPAO and 18F-FDG PET/CT scan].
    Banzo I; Quirce R; Martínez-Rodríguez I; Jiménez-Bonilla J; Portilla-Quattrociocchi H; Medina-Quiroz P; Ortega F; Rodríguez E; Mateo I; Vázquez-Higuera JL; de Arcocha M; Carril JM
    Rev Esp Med Nucl; 2011; 30(5):301-6. PubMed ID: 21640440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-carotid endarterectomy changes in cerebral glucose metabolism on (18)F-fluorodeoxyglucose positron emission tomography associated with postoperative improvement or impairment in cognitive function.
    Yoshida K; Ogasawara K; Saura H; Saito H; Kobayashi M; Yoshida K; Terasaki K; Fujiwara S; Ogawa A
    J Neurosurg; 2015 Dec; 123(6):1546-54. PubMed ID: 26230467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Positron emission tomography scans obtained for the evaluation of cognitive dysfunction.
    Silverman DH; Mosconi L; Ercoli L; Chen W; Small GW
    Semin Nucl Med; 2008 Jul; 38(4):251-61. PubMed ID: 18514081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic value of FDG-PET and HMPAO-SPET in patients with mild dementia and mild cognitive impairment: metabolic index and perfusion index.
    Döbert N; Pantel J; Frölich L; Hamscho N; Menzel C; Grünwald F
    Dement Geriatr Cogn Disord; 2005; 20(2-3):63-70. PubMed ID: 15908747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cerebral glucose metabolism in preclinical and prodromal Alzheimer's disease.
    Herholz K
    Expert Rev Neurother; 2010 Nov; 10(11):1667-73. PubMed ID: 20977325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Positron emission tomography imaging in dementia.
    Herholz K; Carter SF; Jones M
    Br J Radiol; 2007 Dec; 80 Spec No 2():S160-7. PubMed ID: 18445746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD.
    Mosconi L
    Eur J Nucl Med Mol Imaging; 2005 Apr; 32(4):486-510. PubMed ID: 15747152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study.
    Drzezga A; Lautenschlager N; Siebner H; Riemenschneider M; Willoch F; Minoshima S; Schwaiger M; Kurz A
    Eur J Nucl Med Mol Imaging; 2003 Aug; 30(8):1104-13. PubMed ID: 12764551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PET of brain amyloid and tau in mild cognitive impairment.
    Small GW; Kepe V; Ercoli LM; Siddarth P; Bookheimer SY; Miller KJ; Lavretsky H; Burggren AC; Cole GM; Vinters HV; Thompson PM; Huang SC; Satyamurthy N; Phelps ME; Barrio JR
    N Engl J Med; 2006 Dec; 355(25):2652-63. PubMed ID: 17182990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blood metabolite markers of cognitive performance and brain function in aging.
    Simpson BN; Kim M; Chuang YF; Beason-Held L; Kitner-Triolo M; Kraut M; Lirette ST; Windham BG; Griswold ME; Legido-Quigley C; Thambisetty M
    J Cereb Blood Flow Metab; 2016 Jul; 36(7):1212-23. PubMed ID: 26661209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Covariance PET patterns in early Alzheimer's disease and subjects with cognitive impairment but no dementia: utility in group discrimination and correlations with functional performance.
    Scarmeas N; Habeck CG; Zarahn E; Anderson KE; Park A; Hilton J; Pelton GH; Tabert MH; Honig LS; Moeller JR; Devanand DP; Stern Y
    Neuroimage; 2004 Sep; 23(1):35-45. PubMed ID: 15325350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cognitive correlates of α4β2 nicotinic acetylcholine receptors in mild Alzheimer's dementia.
    Sabri O; Meyer PM; Gräf S; Hesse S; Wilke S; Becker GA; Rullmann M; Patt M; Luthardt J; Wagenknecht G; Hoepping A; Smits R; Franke A; Sattler B; Tiepolt S; Fischer S; Deuther-Conrad W; Hegerl U; Barthel H; Schönknecht P; Brust P
    Brain; 2018 Jun; 141(6):1840-1854. PubMed ID: 29672680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CSF biomarkers, impairment of cerebral hemodynamics and degree of cognitive decline in Alzheimer's and mixed dementia.
    Stefani A; Sancesario G; Pierantozzi M; Leone G; Galati S; Hainsworth AH; Diomedi M
    J Neurol Sci; 2009 Aug; 283(1-2):109-15. PubMed ID: 19278690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SPECT for differential diagnosis of dementia and correlation of rCBF with cognitive impairment.
    Osimani A; Ichise M; Chung DG; Pogue JM; Freedman M
    Can J Neurol Sci; 1994 May; 21(2):104-11. PubMed ID: 8087734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebral metabolic correlates of the clinical dementia rating scale in mild cognitive impairment.
    Perneczky R; Hartmann J; Grimmer T; Drzezga A; Kurz A
    J Geriatr Psychiatry Neurol; 2007 Jun; 20(2):84-8. PubMed ID: 17548777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in local cerebral blood flow by neuroactivation and vasoactivation in patients with impaired cognitive function.
    Knapp WH; Dannenberg C; Marschall B; Zedlick D; Löschmann K; Bettin S; Barthel H; Seese A
    Eur J Nucl Med; 1996 Aug; 23(8):878-88. PubMed ID: 8753675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discriminative Power of Arterial Spin Labeling Magnetic Resonance Imaging and 18F-Fluorodeoxyglucose Positron Emission Tomography Changes for Amyloid-β-Positive Subjects in the Alzheimer's Disease Continuum.
    Tosun D; Schuff N; Jagust W; Weiner MW;
    Neurodegener Dis; 2016; 16(1-2):87-94. PubMed ID: 26560336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia?
    Jagust W; Reed B; Mungas D; Ellis W; Decarli C
    Neurology; 2007 Aug; 69(9):871-7. PubMed ID: 17724289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome.
    Silverman DH; Small GW; Chang CY; Lu CS; Kung De Aburto MA; Chen W; Czernin J; Rapoport SI; Pietrini P; Alexander GE; Schapiro MB; Jagust WJ; Hoffman JM; Welsh-Bohmer KA; Alavi A; Clark CM; Salmon E; de Leon MJ; Mielke R; Cummings JL; Kowell AP; Gambhir SS; Hoh CK; Phelps ME
    JAMA; 2001 Nov; 286(17):2120-7. PubMed ID: 11694153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.